Production (Stage)
D
Candel Therapeutics, Inc. CADL
$5.16 $0.030.59% NASDAQ
Recommendation
Prev Close
$5.13
Volume
731,251
Avg Vol (90D)
1,073,643
Market Cap
$257.03M
Dividend & Yield
--
52-Week Range
$3.79 - $14.60
P/E (TTM)
--
EPS (TTM)
-$1.34
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
6/15/2025 - Simply Wall St
Candel Therapeutics (CADL, $5.13) price may climb as it broke lower Bollinger Band on Jun 13, 2025
6/14/2025 - Tickeron - Technical Analysis
Candel Therapeutics (CADL, $5.36) Moving Average Convergence Divergence (MACD) Histogram turned negative on June 12, 2025
6/13/2025 - Tickeron - Stocks
Candel Therapeutics (CADL, $5.36) Stochastic Oscillator left the oversold zone on June 12, 2025
6/13/2025 - Tickeron - Stocks
Candel Therapeutics (CADL, $5.46) entered Downtrend as Momentum indicator drops below 0 level on Jun 11, 2025
6/12/2025 - Tickeron - Stocks
Bank of America Corp DE Buys 44,952 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)
6/11/2025 - MarketBeat
Small cap wrap: HIVE Digital, TNR Gold, Candel Therapeutics...
6/6/2025 - Proactive Investors - UK
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
6/6/2025 - GuruFocus
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors CADL Stock News
6/6/2025 - GuruFocus
Candel Therapeutics (CADL) Welcomes New Board Member CADL Stock News
6/6/2025 - GuruFocus
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board
6/6/2025 - Proactive Investors - UK
Candel Therapeutics appoints Radhakrishnan to board of directors
6/6/2025 - The Fly
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
6/6/2025 - Globe Newswire
Candel Therapeutics (CADL, $5.55) entered Uptrend as Momentum indicator ascends above 0 level on Jun 05, 2025
6/6/2025 - Tickeron - Stocks
Candel Therapeutics (CADL, $5.6) entered Downtrend as Momentum indicator drops below 0 level on Jun 04, 2025
6/5/2025 - Tickeron - Stocks
Candel Therapeutics to hold a conference call
6/3/2025 - The Fly
Candel Therapeutics to hold a conference call
6/3/2025 - TipRanks Financial Blog
Candel Therapeutics to hold a conference call
6/3/2025 - The Fly
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
6/2/2025 - Zacks Investment Research
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
5/29/2025 - Zacks Investment Research
Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE...
5/28/2025 - Proactive Investors - UK
Market movers: GameStop, Okta, Abercrombie, Candel Therapeutics...
5/28/2025 - Proactive Investors - UK
Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409
5/28/2025 - GuruFocus
Candel Therapeutics Stock Soars On FDA's RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy
5/28/2025 - Stocktwits News Feed
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?
5/28/2025 - Benzinga
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$31.87M
EBIT (TTM)
-$32.86M
Net Income (TTM)
-$39.58M
Balance Sheet
Total Assets (Q)
$95.91M
Total Debt (Q)
$10.91M
Total Liabilities (Q)
$21.23M
Book Value Per Share (Q)
$1.52
Cash Flow
Cash from Operations (TTM)
-$27.20M
Cash from Investing (TTM)
-$12.00K
Cash from Financing (TTM)
$93.67M
Net Change in Cash (TTM)
$66.45M
Filings
Filing Date
Tuesday, May 13, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
0.79
7-Day Total Return
-7.03%
30-Day Total Return
-2.27%
60-Day Total Return
-37.45%
90-Day Total Return
-35.74%
Year to Date Total Return
-42.60%
1-Year Total Return
-29.22%
2-Year Total Return
232.90%
3-Year Total Return
50.44%
5-Year Total Return
--
52-week Low
Nov 15, 2024 - $3.79
52-week High
Dec 11, 2024 - $14.60
Valuation
Market Cap
$257.03M - Micro Cap
Enterprise Value
$175.77M
Price/Sales (TTM)
--
Price/Book (Q)
3.38
Dividends and Shares
Shares Outstanding
54.77M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.candeltx.com
Phone Number
617 916 5445
Address
117 Kendrick Street
Needham, MA 02494
Country
United States
Year Founded
2003
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the... more
NASDAQ 06/16/2025 4:00PM Eastern Quotes delayed